Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
7.395 USD | -0.74% | -4.14% | -39.46% |
09/05 | Pulse Biosciences, Inc. Announces First U.S. Procedure with the CellFX nsPFA Percutaneous Electrode System | CI |
07/05 | Transcript : Pulse Biosciences, Inc., Q1 2024 Earnings Call, May 07, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration1st Jan change | Capi. | |
---|---|---|
-39.46% | 411M | |
+11.30% | 226B | |
+9.29% | 188B | |
+13.20% | 137B | |
+26.00% | 108B | |
+0.34% | 63.19B | |
+11.86% | 52.26B | |
+5.62% | 51B | |
+6.67% | 43.89B | |
+5.39% | 38.07B |
- Stock Market
- Equities
- PLSE Stock
- News Pulse Biosciences, Inc.
- Pulse Biosciences Cleared to Start Catheter Ablation Feasibility Trial; Set to File Application for Cardiac Clamp; Shares Rise